India’s pharmacy ecosystem is once again at a crossroads. The All India Organisation of Chemists and Druggists (AIOCD) has written to the Prime Minister seeking urgent intervention to halt the operations of illegal e-pharmacies and to withdraw the proposed GSR 817(E) 220 notification, which the body believes could weaken drug regulatory oversight.

At the heart of the concern is patient safety. According to AIOCD, several online platforms continue to sell prescription medicines without valid licences, proper prescriptions, or pharmacist supervision. This, they argue, opens the door to misuse of antibiotics, narcotics, and high-risk drugs a scenario that could worsen antimicrobial resistance and medication abuse.

The organisation has also flagged the regulatory imbalance between traditional pharmacies and digital players. While brick-and-mortar chemists are subject to routine inspections, strict licensing, and storage norms, AIOCD claims many e-pharmacies operate in legal grey zones with limited accountability.

GSR 817(E) 220 has emerged as a flashpoint. AIOCD fears the notification may legitimise or dilute scrutiny of online medicine sales without first establishing a strong regulatory framework. They argue that digital expansion should not come at the cost of consumer protection or ethical dispensing practices.

At the same time, the issue reflects a broader national dilemma how to balance innovation and convenience with safety and compliance. E-pharmacies offer accessibility, especially for chronic patients and remote areas, but without clear rules and enforcement, the risks multiply.

AIOCD’s appeal underscores a growing demand from industry stakeholders for clear laws, strict enforcement, and a level playing field. As India pushes toward digital health transformation, the message from retail pharmacists is clear: technology must strengthen healthcare not bypass its safeguards.